Duke Spine Outcome Study (DSOS)

NCT04217525 | Suspended

• 1 other identifier: Pro00101198
• Study Type: observational
• Target: 900
• Locations: 1 country
• Sites: 1

Brief Summary

The primary goal of this registry is to increase the knowledge about spine tumors and other spine disorders to guide appropriate management strategies for the future. This registry will include the review of medical records, data collection for health related quality of life questionnaires, and collected tissues and samples. The study will require obtaining spinal lesions (tumor, etc.), blood, and bone marrow samples (from non-lesional bone) from selected patients, which will be collected during your surgery.

Conditions

Spinal Tumor; Spinal Disorder

Outcome Measures

Primary Outcomes (6)

• Change in Quality of Life as measured by Spine Cancer Outcomes Questionnaire (SCOQ)

  It is made up of 5 domains: physical function, neural function, pain, mental health and social function. It was developed as a comparison to the 36-Item Short Form Survey (SF-36) for patients with spine tumors. The reliability and validity of this questionnaire will be compared with the SF-36v2.

  Baseline, 6, 12, 26, 52, 104 weeks

• Change in Pain Score as measured by Pain Numeric Rating Scale (NRS)

  The Pain NRS is an 11-point horizontal scale where the end points are the extremes of no pain (0) and pain as bad as it could be, or worst pain (10). It measures subjective intensity of pain and the patient rates his/her overall or average daily pain.

  Baseline, 6, 12, 26, 52, 104 weeks

• Change in Quality of Life as measured by SF-36 version 2

  Short-form health survey with 36 questions

  Baseline, 6, 12, 26, 52, 104 weeks

• Change in Health Status as measured by EQ-5D

  It contains 5 questions and provides a simple descriptive profile and a single index value for health status.

  Baseline, 6, 12, 26, 52, 104 weeks

• Change in Daily Living Abilities as measured by Eastern Cooperative Oncology Group (ECOG) Performance Status

  Grade 0 = Fully active to 5 = Dead

  Baseline, 6, 12, 26, 52, 104 weeks

• Change in Neurological Function as measured by International Standards Neurological Classification of Spinal Cord Injury (ISNCSCI)

  ISNCSCI is a standardized examination to determine neurologic function and has been a standard clinical assessment for patients with neurological deficit.

  Baseline, 6, 12, 26, 52, 104 weeks

Study Arms (2)

Spinal Disorders

This group includes patients with any spinal deformity or disorder coming in for treatment.

Spinal Tumors

This group includes patients with spinal tumors or metastasis of the spine, coming in for treatment.

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with spinal disorders or spinal tumors.

You may qualify if:

• Age between 18 and 85 years.
• Able to read and write local language at an elementary level.
• Diagnosis of primary or metastatic tumor of the spine ); or
• Infection of the spine; or
• Instability of the spine; or
• Injury of the spine.
• Accessibility for treatment and follow up.
• Patient consent obtained according to Duke institutional policy.
• Age between 18 and 85 years.
• Spine surgery to be performed at Duke University Medical Center (DUMC) under the auspices of the neurosurgery program.
• No concurrent cancer diagnosis.
• Accessibility for treatment and follow up.
• Patient consent obtained according to Duke institutional policy.

You may not qualify if:

• History of substance abuse (recreational drugs, alcohol) within 12 months prior to screening
• Is a prisoner.
• A disease or condition that would, in opinion of the investigator, preclude accurate evaluation
• (e.g. significant psychiatric disease), or that would impair the ability of the patient to receive protocol treatment or comply with protocol.
• Pregnant or breast feeding during the study period (women of child-bearing potential will require a negative serum pregnancy test within 30 days of enrollment).
• Active infection, or fever of unknown origin.
• Inflammatory bowel disease.
• Systemic lupus erythematosus.
• Rheumatoid arthritis, or other autoimmune disease.
• History of or active hematologic or bone marrow diseases, including but not limited to diagnosed lymphomas, leukemias, sickle cell or other anemias not associated with their current condition.
• Polycythemia vera.
• Known or suspected immunodeficiency or Human Immunodeficiency Virus (HIV).
• Hematocrit \< 24% pre-operatively.

Sponsors & Collaborators

• Duke University: lead

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Will collect up to 60mL of blood and 5mL of bone marrow.

MeSH Terms

Conditions

Spinal Cord Neoplasms; Spinal Diseases

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Bone Diseases; Musculoskeletal Diseases

Study Officials

• Courtney R. Goodwin, M.D., PhD

  Duke University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 31, 2019
• First Posted: January 3, 2020
• Study Start: December 3, 2019
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: January 20, 2026

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)